Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
2
institutions
Market cap
$3.5B
45M shares
52-week range
$47.32 – $87.32
70% from low
Sector
SURGICAL & MEDICAL INSTRUMENTS & APPARATUS
Exchange
NYSE
CS
Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces. As such, the company operates under three segments: plasma, blood center, and hospital. The company emphasizes its plasma and hospital segments due to their robust growth potential, whereas the blood center segment tends to be constrained by higher competition. Product revenue is driven by demand for disposable blood component collection and processing sets and the related equipment needed for proper functionality.
www.haemonetics.comNo one on the platform currently holds HAE.
| Institution | Shares | Reported |
|---|---|---|
| Bridgewater Associatesas of 2026-03-31 | 48,377 | $2.7M |
| Renaissance Technologiesas of 2026-03-31 | 43,200 | $2.4M |
| Execution date | Ratio |
|---|---|
| 2012-12-03 | 2-for-1 |
No one on the platform has traded HAE yet.
$HAE https://anachart.com/wp-content/uploads/2026/06/1781690468_soc-img.jpg
View on StockTwits ↗$HAE On my list, wanted to buy today but did not like the open, any catalysts coming?
View on StockTwits ↗$HAE Excellent article that nails exactly where HAE stands right now. So if you want to update your HAE knowledge or get acquainted with HAE, this is a must read. https://everyticker.com/quote/HAE/analysis/margin-expansion-meets-plasma-innovation-haemonetics-medtech-transformation-nyse-hae
View on StockTwits ↗$HAE Revenue growth has been inconsistent, with several quarters showing declines or only low-single-digit growth.*
View on StockTwits ↗$HAE - Haemonetics Corporation - 10K - Updated Risk Factors Risk shifts highlight new concentration (a single customer now 13% of net revenue), execution risk from a major global ERP rollout, added regulatory burden and uncertainty from FDA’s new QMSR and evolving Brexit/Swexit rules, plus clarified but still evolving global tax exposure despite OBBBA and G7 Pillar Two relief. #MedicalDevices #CustomerConcentration #ERPImplementationRisk #RegulatoryCompliance #GlobalTaxExposure 🟢 Added 🟠 Removed https://d-risk.ai/HAE/10-K/2026-05-20
View on StockTwits ↗$HAE Share Price: $56.85 Contract Selected: Dec 18, 2026 $70 Calls Buy Zone: $1.66 – $2.05 Target Zone: $3.03 – $3.70 Potential Upside: 73% ROI Time to Expiration: 212 Days | Updates via https://fxcapta.com/stockinfo/
View on StockTwits ↗$HAE Current Stock Price: $52.76 Contracts to trade: $55.0 HAE May 15 2026 Call Entry: $0.10 Exit: $0.13 ROI: 35% Hold ~27 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.